Maternal thyroid hormones (THs) are essential for the developing newborns(El-bakry et al.,
On the other hand, several investigations have revealed the link between the hypothyroidism and dyslipidemia (Stone, 1994 (Raza and Mahmood, 2013) . In fact, Hueston and Pearson (2004) observed that the subclinical hypothyroidism did not has any effect on the lipid profile if we adjust the race, sex, age and use of lipid-lowering drugs. In addition, Knudsen et al (2005) recorded that any change in the activities of the thyroid gland can be harmful to the body mass index (BMI) and cause obesity. On the other hand, the presence of insulin resistance can reinforce the effect of hypothyroidism on the lipid profile (Bakker et al., 2001; Chubb et al., 2005) .
On the basis of these observations, I hypothesized the following: (1)THs, perhaps of maternal origin, play vital roles in the homeostasis of the fetal lipid profile; (2) the maternal thyroid disorders (hypothyroidism) may perturb the lipid homeostasis (contents, metabolism and distributions) in liver and adipose tissues during the gestation and lactation; (3) the maternal hypothyroidism may cause fetal/neonatal dyslipidemia; and (4) the maternal hypothyroidism may delay the fetal/neonatal development. Thus, adjusting the levels of maternal, fetal and neonatal THs and thyroid-stimulating hormone (TSH) can easily prevent this disturbance during the gestation and lactation. Future studies are required to understand the connection between the genomic and non-genomic actions of THs during the abnormal conditions (hypothyroidism or hyperthyroidism during the gestation and lactation) and fetal dyslipidemia. This view will assist to prevent not only the thyroid dysfunction during the critical developmental periods but also the cardiovascular disease and obesity (predominant diseases in our life). Thus, the association between the molecular and developmental investigations is warranted.
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